Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (MRNS) will be presenting at the TD Cowen 44th Annual Healthcare Conference and the Leerink Partners 2024 Global Biopharma Conference in March. The company is dedicated to developing innovative therapeutics for seizure disorders.
Positive
None.
Negative
None.
RADNOR, Pa.--(BUSINESS WIRE)--
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present at and participate in the following conferences in March.
The TD Cowen 44th Annual Healthcare Conference in Boston, MA
Panel Discussion: Orphan Epilepsies - March 6 at 10:30 a.m. E.T.
Leerink Partners 2024 Global Biopharma Conference in Miami, FL
Presentation - March 11 at 4:00 p.m. E.T.
Links to the events can be accessed on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.